New combo therapy shows promise for older brain cancer patients

NCT ID NCT04022980

Completed Disease control Sponsor: Wake Forest University Health Sciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested the safety of the drug nivolumab given after standard chemotherapy in 14 older adults (65 and up) with primary CNS lymphoma, a rare brain cancer. The goal was to see if adding nivolumab could help keep the cancer from coming back for at least 2 years. The study focused on finding a safe dose and checking how well it worked, but it is not a cure and requires ongoing monitoring.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

disorder of orbital region lymphoma Neurologic Manifestations primary central nervous system lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRAIN AND NERVOUS SYSTEM EYE AND ORBIT

Contacts and locations

Show contact details

Locations

Dana Farber Cancer Institute

Brookline, Massachusetts, 02215, United States
Levine Cancer Institute

Charlotte, North Carolina, 28204, United States
The University of Texas - MD Anderson Cancer Center

Houston, Texas, 77030, United States
UNC Hospitals, The University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, 27514, United States